Press release
Alzheimer's Drugs Market Analysis 2024 -2033: Forecasted Market Size, Top Segments, And Largest Region | AbbVie Inc., Daiichi Sankyo Company Limited, F Hoffmann-La Roche AG, Merck & Co Inc., Novartis AG
Alzheimer's Drugs Market Characteristics
The Business Research Company offers in-depth market insights through Alzheimer's Drugs Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The alzheimer's drugs market size has grown strongly in recent years. It will grow from $8.64 billion in 2023 to $9.44 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to rise in alzheimer's disease cases, investments in research and development, improved understanding of disease mechanisms, global health initiatives, public awareness and education..
The alzheimer's drugs market size is expected to see strong growth in the next few years. It will grow to $13.32 billion in 2028 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to precision medicine approaches, focus on disease modification, biomarker identification and validation, patient-centric drug development, focus on non-pharmacological interventions.. Major trends in the forecast period include diverse therapeutic approaches, digital health solutions, regenerative medicine, advancements in diagnostic technologies, artificial intelligence (ai) in drug discovery, partnerships and collaborations..
Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=9040&type=smp
Market Segmentation:
The alzheimer's drugs market covered in this report is segmented -
1) By Drugs: Donepezil, Rivastigmine, Galantamine, Memantine
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By Application: Early To Moderate Stages, Moderate To Severe Stages
Major Driver - Rising Prevalence Of Alzheimer'S Disease To Drive Market Growth
The rising prevalence of Alzheimer's disease is expected to propel the growth of the Alzheimer's drugs market going forward. Alzheimer's disease is a neurologic condition that worsens over time and causes both brain shrinkage and cell death. Drugs for Alzheimer's disease are used to treat memory loss, problems with thinking and reasoning, and difficulties with everyday living. Drugs for Alzheimer's can enhance the quality of life and help maintain independence. For instance, in June 2020, according to the 2022 Alzheimer's Disease Facts and Figures report by The Alzheimer's Association, a US-based non-profit and voluntary health organization in Alzheimer's care, support and research. In 2022, there were 6.5 million Americans 65 and older who have Alzheimer's disease. About 1 in 9 Americans (or 10.7% of the total population) who are 65 or older have Alzheimer's disease. The percentage of those who have Alzheimer's disease rises with age: 5.0% of those between the ages of 65 and 74, 13.1% of those between the ages of 75 and 84, and 33.2% of those beyond the age of 85. By 2050, there are expected to be 88 million Americans aged 65 and older, up from 58 million in 2021. Therefore, the increasing prevalence of Alzheimer's disease is driving the growth of the Alzheimer's drugs market.
Competitive Landscape:
Major companies operating in the alzheimer's drugs market report are AbbVie Inc., Daiichi Sankyo Company Limited, F Hoffmann-La Roche AG, Merck & Co Inc., Novartis AG, Biogen Inc., AstraZeneca PLC, Eisai Co Ltd., Eli Lilly and Company, H Lundbeck A/S, Pfizer Inc., Allergan PLC., Johnson & Johnson, Lupin Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Neurotrope Inc., AC Immune SA, Adamas Pharmaceuticals Inc, Alzheon Inc., Anavex Life Sciences Corp, Axsome Therapeutics Inc., Cassava Sciences Inc., Cognition Therapeutics Inc., Cortexyme Inc., Denali Therapeutics Inc, EIP Pharma Inc., Enlivex Therapeutics Ltd., FORUM Pharmaceuticals Inc., Genentech Inc., Green Valley Pharmaceuticals LLC, Intra-Cellular Therapies Inc., Karuna Therapeutics Inc., Neurim Pharmaceuticals Ltd .
Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report
Top Trend - Technological Advancements Driving Innovation In Alzheimer'S Drugs Market
Technological advancements have emerged as a key trend gaining popularity in the Alzheimer's disease market. Major companies operating in the Alzheimer's disease market are focused on innovating new technologies to sustain their position in the market. For instance, in January 2021, iMediSync, a South Korea-based healthcare platform company, launched iSyncBrain, an EEG digital biomarker for early Alzheimer's dementia diagnosis on their AI cloud platform. They also provide customized NIR-LED neuromodulation using their future cutting-edge headset, iSyncWaveTM, to increase neural activity, employing AI analytics and brain mapping techniques. To prevent dementia in the preclinical stage, the iSyncBrain® MCI classifier screens and distinguishes between amnestic moderate cognitive impairment (MCI) of the Alzheimer or non-Alzheimer type. This has undergone multicenter clinical testing with over 90% accuracy rates.
The Table Of Content For The Market Report Include:
1. Executive Summary
2. Alzheimer's Drugs Market Characteristics
3. Alzheimer's Drugs Market Trends And Strategies
4. Alzheimer's Drugs Market - Macro Economic Scenario
5. Alzheimer's Drugs Market Size And Growth
…..
27. Alzheimer's Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx
About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzheimer's Drugs Market Analysis 2024 -2033: Forecasted Market Size, Top Segments, And Largest Region | AbbVie Inc., Daiichi Sankyo Company Limited, F Hoffmann-La Roche AG, Merck & Co Inc., Novartis AG here
News-ID: 3424475 • Views: …
More Releases from The Business research company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Alzheimer
Alzheimer Therapeutics Market Breakthrough Innovations and Increasing Treatment …
The Alzheimer Therapeutics Market is rapidly evolving as disease-modifying therapies, early-stage diagnostic tools, and biomarker-driven treatment approaches reshape global management of Alzheimer's disease (AD). As one of the most prevalent neurodegenerative conditions, Alzheimer's affects millions of older adults worldwide. With recent regulatory approvals of anti-amyloid monoclonal antibodies, enhanced imaging technology, and increased R&D investment, the market is experiencing unprecedented momentum.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/51928
Key Takeaways
• Disease-modifying…
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
